Euroclinica Limited 07513908 false 2023-03-01 2024-02-29 2024-02-29 The principal activity of the company is to provide consultancy on clinical affairs. Digita Accounts Production Advanced 6.30.9574.0 true true 07513908 2023-03-01 2024-02-29 07513908 2024-02-29 07513908 bus:OrdinaryShareClass1 2024-02-29 07513908 bus:OrdinaryShareClass2 2024-02-29 07513908 core:CurrentFinancialInstruments 2024-02-29 07513908 core:CurrentFinancialInstruments core:WithinOneYear 2024-02-29 07513908 core:FurnitureFittingsToolsEquipment 2024-02-29 07513908 bus:SmallEntities 2023-03-01 2024-02-29 07513908 bus:AuditExemptWithAccountantsReport 2023-03-01 2024-02-29 07513908 bus:FilletedAccounts 2023-03-01 2024-02-29 07513908 bus:SmallCompaniesRegimeForAccounts 2023-03-01 2024-02-29 07513908 bus:RegisteredOffice 2023-03-01 2024-02-29 07513908 bus:CompanySecretaryDirector1 2023-03-01 2024-02-29 07513908 bus:OrdinaryShareClass1 2023-03-01 2024-02-29 07513908 bus:OrdinaryShareClass2 2023-03-01 2024-02-29 07513908 bus:PrivateLimitedCompanyLtd 2023-03-01 2024-02-29 07513908 core:FurnitureFittings 2023-03-01 2024-02-29 07513908 core:FurnitureFittingsToolsEquipment 2023-03-01 2024-02-29 07513908 countries:England 2023-03-01 2024-02-29 07513908 2023-02-28 07513908 core:FurnitureFittingsToolsEquipment 2023-02-28 07513908 2022-03-01 2023-02-28 07513908 2023-02-28 07513908 bus:OrdinaryShareClass1 2023-02-28 07513908 bus:OrdinaryShareClass2 2023-02-28 07513908 core:CurrentFinancialInstruments 2023-02-28 07513908 core:CurrentFinancialInstruments core:WithinOneYear 2023-02-28 07513908 core:FurnitureFittingsToolsEquipment 2023-02-28 iso4217:GBP xbrli:pure xbrli:shares

Registration number: 07513908

Euroclinica Limited

Unaudited Filleted Financial Statements

for the Year Ended 29 February 2024

 

Euroclinica Limited

Contents

Company Information

1

Statement of financial position

2 to 3

Notes to the Unaudited Financial Statements

4 to 8

 

Euroclinica Limited

Company Information

Director

Ms R Johnson

Company secretary

Ms R Johnson

Registered office

19 King Street
King's Lynn
Norfolk
PE30 1HB

Accountants

Hayhow & Co
Chartered Certified Accountants & Business Advisers
19 King Street
King's Lynn
Norfolk
PE30 1HB

 

Euroclinica Limited

(Registration number: 07513908)
Statement of financial position as at 29 February 2024

Note

2024
£

2023
£

Fixed assets

 

Tangible assets

4

379

509

Current assets

 

Stocks

5

13,642

9,073

Debtors

6

9,311

751

Cash at bank and in hand

 

8,203

38,859

 

31,156

48,683

Creditors: Amounts falling due within one year

7

(22,629)

(22,264)

Net current assets

 

8,527

26,419

Total assets less current liabilities

 

8,906

26,928

Provisions for liabilities

(84)

(97)

Net assets

 

8,822

26,831

Capital and reserves

 

Called up share capital

8

100

100

Retained earnings

8,722

26,731

Shareholders' funds

 

8,822

26,831

For the financial year ending 29 February 2024 the company was entitled to exemption from audit under section 477 of the Companies Act 2006 relating to small companies.

Director's responsibilities:

The members have not required the company to obtain an audit of its accounts for the year in question in accordance with section 476; and

The director acknowledges her responsibilities for complying with the requirements of the Act with respect to accounting records and the preparation of accounts.

These financial statements have been prepared in accordance with the special provisions relating to companies subject to the small companies regime and in accordance with FRS 102 'The Financial Reporting Standard applicable in the UK and Republic of Ireland'.

These financial statements have been delivered in accordance with the provisions applicable to companies subject to the small companies regime. As permitted by section 444 (5A) of the Companies Act 2006, the director has not delivered to the registrar a copy of the Statement of comprehensive income.

Approved and authorised by the director on 9 April 2024
 

 

Euroclinica Limited

(Registration number: 07513908)
Statement of financial position as at 29 February 2024

.........................................
Ms R Johnson
Company secretary and director

 

Euroclinica Limited

Notes to the Unaudited Financial Statements for the Year Ended 29 February 2024

1

General information

The company is a private company limited by share capital, incorporated in England.

The address of its registered office is:
19 King Street
King's Lynn
Norfolk
PE30 1HB

The principal place of business is:
7 Dow Close
Norwich
Norfolk
NR5 9HW

These financial statements were authorised for issue by the director on 9 April 2024.

2

Accounting policies

Summary of significant accounting policies and key accounting estimates

The principal accounting policies applied in the preparation of these financial statements are set out below. These policies have been consistently applied to all the years presented, unless otherwise stated.

Statement of compliance

These financial statements have been prepared in accordance with Financial Reporting Standard 102 Section 1A smaller entities - 'The Financial Reporting Standard applicable in the United Kingdom and Republic of Ireland' and the Companies Act 2006 (as applicable to companies subject to the small companies' regime).

Basis of preparation

These financial statements have been prepared using the historical cost convention except that as disclosed in the accounting policies certain items are shown at fair value.

Going concern

The financial statements have been prepared on a going concern basis.

Revenue recognition

Turnover comprises the fair value of the consideration received or receivable for the sale of goods and provision of services in the ordinary course of the company’s activities. Turnover is shown net of sales/value added tax, returns, rebates and discounts.

The company recognises revenue when:
The amount of revenue can be reliably measured;
it is probable that future economic benefits will flow to the entity;
and specific criteria have been met for each of the company's activities.

 

Euroclinica Limited

Notes to the Unaudited Financial Statements for the Year Ended 29 February 2024

Foreign currency transactions and balances

Transactions in foreign currencies are initially recorded at the functional currency rate prevailing at the date of the transaction. Monetary assets and liabilities denominated in foreign currencies are retranslated into the respective functional currency of the entity at the rates prevailing on the reporting period date. Non-monetary items carried at fair value that are denominated in foreign currencies are retranslated at the rate on the date when the fair value is re-measured.

Non-monetary items measured in terms of historical cost in a foreign currency are not retranslated.

Tax

The tax expense for the period comprises current and deferred tax. Tax is recognised in profit or loss, except that a change attributable to an item of income or expense recognised as other comprehensive income is also recognised directly in other comprehensive income.

The current income tax charge is calculated on the basis of tax rates and laws that have been enacted or substantively enacted by the reporting date in the countries where the company operates and generates taxable income.

Deferred tax is recognised in respect of all timing differences between taxable profits and profits reported in the financial statements.

Unrelieved tax losses and other deferred tax assets are recognised when it is probable that they will be recovered against the reversal of deferred tax liabilities or other future taxable profits.

Deferred tax is measured using the tax rates and laws that have been enacted or substantively enacted by the reporting date and that are expected to apply to the reversal of the timing difference.

Tangible assets

Tangible assets are stated in the statement of financial position at cost, less any subsequent accumulated depreciation and subsequent accumulated impairment losses.

The cost of tangible assets includes directly attributable incremental costs incurred in their acquisition and installation.

Depreciation

Depreciation is charged so as to write off the cost of assets, other than land and properties under construction over their estimated useful lives, as follows:

Asset class

Depreciation method and rate

Fixtures, Fittings and Equipment

25% Reducing balance

Cash and cash equivalents

Cash and cash equivalents comprise cash on hand and call deposits, and other short-term highly liquid investments that are readily convertible to a known amount of cash and are subject to an insignificant risk of change in value.

Trade debtors

Trade debtors are amounts due from customers for merchandise sold or services performed in the ordinary course of business.

Trade debtors are recognised initially at the transaction price. They are subsequently measured at amortised cost using the effective interest method, less provision for impairment. A provision for the impairment of trade debtors is established when there is objective evidence that the company will not be able to collect all amounts due according to the original terms of the receivables.

 

Euroclinica Limited

Notes to the Unaudited Financial Statements for the Year Ended 29 February 2024

Stocks

Stocks are stated at the lower of cost and estimated selling price less costs to complete and sell.

The cost of finished goods and work in progress comprises direct materials and, where applicable, direct labour costs and those overheads that have been incurred in bringing the inventories to their present location and condition. At each reporting date, stocks are assessed for impairment. If stocks are impaired, the carrying amount is reduced to its selling price less costs to complete and sell; the impairment loss is recognised immediately in profit or loss.

Trade creditors

Trade creditors are obligations to pay for goods or services that have been acquired in the ordinary course of business from suppliers. Accounts payable are classified as current liabilities if the company does not have an unconditional right, at the end of the reporting period, to defer settlement of the creditor for at least twelve months after the reporting date. If there is an unconditional right to defer settlement for at least twelve months after the reporting date, they are presented as non-current liabilities.

Trade creditors are recognised initially at the transaction price and subsequently measured at amortised cost using the effective interest method.

Share capital

Ordinary shares are classified as equity. Equity instruments are measured at the fair value of the cash or other resources received or receivable, net of the direct costs of issuing the equity instruments. If payment is deferred and the time value of money is material, the initial measurement is on a present value basis.

Dividends

Dividend distribution to the company’s shareholders is recognised as a liability in the financial statements in the reporting period in which the dividends are declared.

3

Staff numbers

The average number of persons employed by the company (including the director) during the year, was 2 (2023 - 2).

 

Euroclinica Limited

Notes to the Unaudited Financial Statements for the Year Ended 29 February 2024

4

Tangible assets

Furniture, fittings and equipment
 £

Total
£

Cost or valuation

At 1 March 2023

1,554

1,554

At 29 February 2024

1,554

1,554

Depreciation

At 1 March 2023

1,045

1,045

Charge for the year

130

130

At 29 February 2024

1,175

1,175

Carrying amount

At 29 February 2024

379

379

At 28 February 2023

509

509

5

Stocks

2024
£

2023
£

Work in progress

13,642

9,073

6

Debtors

2024
£

2023
£

Trade debtors

8,344

-

Prepayments

699

693

Other debtors

268

58

9,311

751

 

Euroclinica Limited

Notes to the Unaudited Financial Statements for the Year Ended 29 February 2024

7

Creditors

Creditors: amounts falling due within one year

Note

2024
£

2023
£

Due within one year

 

Amounts due to related parties

82

56

Accruals

 

1,363

1,389

Tax liability

21,184

20,819

 

22,629

22,264

8

Share capital

Allotted, called up and fully paid shares

2024

2023

No.

£

No.

£

Ordinary A Shares of £1 each

85

85

85

85

Ordinary B Shares of £1 each

15

15

15

15

100

100

100

100

Each share is entitled to one vote in any circumstances and each share is also entitled pari passu to dividend payments or any other distribution, including a distribution arising from a winding up of the company.